Approaches such as digital PCR have demonstrated improved, assay characteristics and are likely to play an increasing role in the monitoring of myeloproliferative neoplasms. While next-generation sequencing is increasingly valuable as a tool for the diagnosis of myeloproliferative neoplasms, its role in the assessment of minimal residual disease requires further evaluation.
Biomed Res Int